Gabelli Analysts Decrease Earnings Estimates for Hologic, Inc. (HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Gabelli reduced their FY2018 earnings per share (EPS) estimates for shares of Hologic in a report released on Monday. Gabelli analyst S. Wojda now expects that the medical equipment provider will post earnings of $2.25 per share for the year, down from their previous estimate of $2.30. Gabelli also issued estimates for Hologic’s FY2019 earnings at $2.45 EPS, FY2020 earnings at $2.65 EPS and FY2021 earnings at $2.85 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same quarter last year, the business earned $0.52 earnings per share. The business’s revenue for the quarter was up 7.7% on a year-over-year basis.

HOLX has been the topic of a number of other research reports. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Thursday, January 4th. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and raised their price objective for the company from $45.00 to $50.00 in a research note on Friday, December 8th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 price objective (up previously from $46.00) on shares of Hologic in a research note on Tuesday, December 5th. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research note on Wednesday, December 20th. Finally, Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $48.00.

Hologic (HOLX) traded down $0.24 during midday trading on Wednesday, hitting $37.80. 3,386,100 shares of the company were exchanged, compared to its average volume of 2,916,220. Hologic has a fifty-two week low of $35.33 and a fifty-two week high of $46.80. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,519.17, a price-to-earnings ratio of 9.97, a PEG ratio of 1.72 and a beta of 0.77.

A number of institutional investors have recently bought and sold shares of HOLX. Parnassus Investments CA boosted its stake in Hologic by 88.6% in the 4th quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after purchasing an additional 6,689,454 shares during the period. Victory Capital Management Inc. boosted its stake in Hologic by 5.8% in the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock worth $265,008,000 after purchasing an additional 342,239 shares during the period. Pictet Asset Management Ltd. boosted its stake in Hologic by 50.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,912,338 shares of the medical equipment provider’s stock worth $106,854,000 after purchasing an additional 974,325 shares during the period. Dimensional Fund Advisors LP boosted its stake in Hologic by 5.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock worth $72,243,000 after purchasing an additional 105,360 shares during the period. Finally, Legal & General Group Plc boosted its stake in Hologic by 3.5% in the 3rd quarter. Legal & General Group Plc now owns 1,426,469 shares of the medical equipment provider’s stock worth $52,333,000 after purchasing an additional 48,577 shares during the period. Hedge funds and other institutional investors own 93.84% of the company’s stock.

In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.88% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gabelli Analysts Decrease Earnings Estimates for Hologic, Inc. (HOLX)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/gabelli-analysts-decrease-earnings-estimates-for-hologic-inc-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply